Evaluation of bergenin in amylase enzyme inhibition and lipid uptake in liver cells
Avaliação da bergenina na inibição da enzima amilase e captação de lipídeos em células hepáticas
Palavras-chave:
Bergenin, Metabolic disease, Antioxidant, Amylase, HepG2Resumo
Changes in the global economy contribute to a sedentary lifestyle and higher caloric intake, increasing the incidence of metabolic diseases. It is estimated that the number of individuals diagnosed with metabolic diseases will increase by 25% by 2030 and 51% by 2045. Natural products have been tested in metabolic diseases with positive results, as shown by bergenin. Thus, this work aimed to evaluate the possible effects of bergenin in models of metabolic disease through in silico and in vitro experimental procedures. Bergenin showed the ability to inhibit protein glycation by 19.88 ± 4.22% in the oxidative pathway and 8.32 ± 1.85% in the non-oxidative pathway. This study showed for the first time that bergenin has the potential to inhibit the α-amylase enzyme (33.89 ± 0.96%) using in silico and in vitro assays. Bergenin was not able to significantly inhibit lipid uptake by the Oil Red method. After these results, it is understood that bergenin has the potential to be better studied as a therapeutic option in metabolic diseases. However, additional in vivo studies are needed to better elucidate the possible pharmacological effects of bergenin in metabolic diseases.
Downloads
Referências
AMBIKA, S.; SARAVANAN, R. Effect of bergenin on hepatic glucose metabolism and insulin signaling in C57BL/6J mice with high fat-diet induced type 2 diabetes. Journal of Applied Biomedicine, v. 14, n. 3, p. 221–227, 2016a.
AMBIKA, S.; SARAVANAN, R. Effect of bergenin on hepatic glucose metabolism and insulin signaling in C57BL/6J mice with high fat-diet induced type 2 diabetes. Journal of Applied Biomedicine, v. 14, n. 3, p. 221–227, 2016b.
ANDRADE-CETTO, A.; BECERRA-JIMÉNEZ, J.; CÁRDENAS-VÁZQUEZ, R. Alfa-glucosidase-inhibiting activity of some Mexican plants used in the treatment of type 2 diabetes. Journal of Ethnopharmacology, v. 116, n. 1, p. 27–32, 2008.
BAJRACHARYA, G. B. Diversity, pharmacology and synthesis of bergenin and its derivatives: potential materials for therapeutic usages. Fitoterapia, v. 101, p. 133–152, 2015.
BERTHOUD, H. R.; NEUHUBER, W. L. Vagal mechanisms as neuromodulatory targets for the treatment of metabolic disease. Annals of the New York Academy of Sciences, v. 1454, n. 1, p. 42–55, 2019.
BROUWERS, O. et al. Overexpression of glyoxalase-I reduces hyperglycemiainduced levels of advanced glycation end products and oxidative stress in diabetic rats. Journal of Biological Chemistry, v. 286, n. 2, p. 1374–1380, 2011.
CASTELO BRANCO, N. V. et al. Effect of Uxi (Endopleura uchi) tea in hepatic steatosis. Rev. Soc. Bras. Clín. Méd, p. 25–29, 2018.
CHEN, Z. et al. Studies on the chemical constituents and anticancer activity of Saxifraga stolonifera (L) Meeb. Bioorganic & Medicinal Chemistry, v. 16, n. 3, p. 1337–1344, 1 fev. 2008.
COSTELLO, K. R.; SCHONES, D. E. Chromatin modifications in metabolic disease: Potential mediators of long-term disease risk. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, v. 10, n. 4, p. 1–12, 2018.
DE OLIVEIRA DOS SANTOS, A. R. et al. Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions. International Journal of Molecular Sciences, v. 22, n. 5, p. 2639, 5 mar. 2021.
DENG, L.-J. et al. Natural products and their derivatives: Promising modulators of tumor immunotherapy. Journal of Leukocyte Biology, v. 108, n. 2, p. 493–508, 2020.
DEVI, N.; DUTTA, J. Tests for in vitro cytotoxicity. International Standard, v. 104, p. 1897–1904, 2017.
EBERHARDT, J. et al. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. Journal of chemical information and modeling, v. 61, n. 8, 2021.
ESLAM, M. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, v. 158, n. 7, p. 1999- 2014.e1, 2020.
FAHED, G. et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. International Journal of Molecular Sciences, v. 23, n. 2, p. 786, 12 jan. 2022.
FAN, Y.; PEDERSEN, O. Gut microbiota in human metabolic health and disease. Nature Reviews. Microbiology, v. 19, n. 1, p. 55–71, jan. 2021.
FÄNDRIKS, L. Roles of the gut in the metabolic syndrome: an overview. Journal of Internal Medicine, v. 281, n. 4, p. 319–336, 2017.
GAO, F. et al. 4-Hydroxyisoleucine improves insulin resistance in HepG2 cells by decreasing TNF-α and regulating the expression of insulin signal transduction proteins. Molecular Medicine Reports, v. 12, n. 5, p. 6555–6560, nov. 2015.
GOH, K. K. et al. Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction. International Journal of Molecular Sciences, v. 23, n. 13, p. 7092, 25 jun. 2022.
GOLDEN, S. H. et al. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes, v. 51, n. 10, p. 3069–3076, out. 2002.
GUSTAVO, R. B. DE O. et al. Stem bark extracts of Endopleura uchi (Huber) Cuatrec: Inhibition of pancreatic lipase and antioxidant activity. Journal of Medicinal Plants Research, v. 11, n. 30, p. 472–479, 2017.
HAY, J. E.; HAYNES, L. J. Bergenin, a C-glycopyranosyl derivative of 4-O-methylgallic acid. Journal of the Chemical Society (Resumed), n. 0, p. 2231–2238, 1958.
IVANOV, S. A. et al. Isolation of a novel catechin from Bergenia rhizomes that has pronounced lipase-inhibiting and antioxidative properties. Fitoterapia, v. 82, n. 2, p. 212–218, 2011.
JAHROMI, M. A. F.; CHANSOURIA, J. P. N.; RAY, A. B. Hypolipidaemic Activity in Rats of Bergenin, the Major Constituent of Flueggea microcarpa. Phytotherapy Research, v. 6, n. 4, p. 180–183, 1992.
JAYAKODY, R. S. et al. Bergenin : a computationally proven promising scaffold for novel galectin-3 inhibitors. Journal of Molecular Modeling, v. 24, n. 9, p. 257–299, 2018.
JIMÉNEZ, J. et al. KDEEP: Protein-Ligand Absolute Binding Affinity Prediction via 3D-Convolutional Neural Networks. Journal of Chemical Information and Modeling, v. 58, n. 2, p. 287–296, 2018.
KASHIMA, Y. et al. Structure-activity relationships of bergenin derivatives effect on α-glucosidase inhibition. Journal of Enzyme Inhibition and Medicinal Chemistry, v. 28, n. 6, p. 1162–1170, 2013.
KEREM, L.; LAWSON, E. A. The Effects of Oxytocin on Appetite Regulation, Food Intake and Metabolism in Humans. International Journal of Molecular Sciences, v. 22, n. 14, p. 7737, 20 jul. 2021.
KHALIFAH, R. G.; BAYNES, J. W.; HUDSON, B. G. Breakthroughs and views. Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions. Biochemical and Biophysical Research Communications, v. 257, n. 2, p. 251–258, 1999.
KIHO, T. et al. Tomato Paste Fraction Inhibiting the Formation of Advanced. Bioscience, Biotechnology, and Biochemistry, v. 68, n. 1, p. 200–205, 2004a.
KIHO, T. et al. Tomato paste fraction inhibiting the formation of advanced glycation end-products. Bioscience, Biotechnology, and Biochemistry, v. 68, n. 1, p. 200–205, 2004b.
KUMAR, R. et al. Type 2 antidiabetic activity of bergenin from the roots of Caesalpinia digyna Rottler. Fitoterapia, v. 83, n. 2, p. 395–401, 2012.
LEE, K. H.; CHOI, E. M. Effects of bergenin on methylglyoxal induced damage in osteoblastic MC3T3-E1 cells. Journal of Appplied Toxicology, v. 1, n. August, p. 1–9, 2017.
LEE, S.-H.; PARK, S.-Y.; CHOI, C. S. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes & Metabolism Journal, v. 46, n. 1, p. 15–37, jan. 2022.
LIANG, J. et al. In vivo and in vitro antimalarial activity of bergenin. Biomedical Reports, v. 2, n. 2, p. 260–264, 2014a.
LIANG, J. et al. In vivo and in vitro antimalarial activity of bergenin. Biomedical Reports, v. 2, n. 2, p. 260–264, mar. 2014b.
LÓPEZ, D. et al. Structurally diverse natural products that cause potassium leakage trigger multicellularity in Bacillus subtilis. Proceedings of the National Academy of Sciences of the United States of America, v. 106, n. 1, p. 280–285, 6 jan. 2009.
MARRERO, S.; ADASHI, E. Y. Noncommunicable Diseases. Seminars in Reproductive Medicine, v. 33, p. 35–40, 2015.
MEDRIKOVA, D. et al. Sex differences during the course of diet-induced obesity in mice: Adipose tissue expandability and glycemic control. International Journal of Obesity, v. 36, n. 2, p. 262–272, 2012a.
MEDRIKOVA, D. et al. Sex differences during the course of diet-induced obesity in mice: adipose tissue expandability and glycemic control. International Journal of Obesity (2005), v. 36, n. 2, p. 262–272, fev. 2012b.
MENDOZA MEZA, D. L.; MEDINA VALDÉS, R. Inhibición in vitro de las enzimas alfa-amilasa y lipasa pancreática por fracciones fenólicas de extractos etanólicos de hojas de Yacón (Smallanthus sonchifolius Poepp. & Endl). Avances en Quimica, v. 10, n. 1, p. 33–40, 2015.
MORENO, D. A. et al. Inhibition of lipid metabolic enzymes using Mangifera indica extracts. Journal of Food, Agriculture and Environment, v. 4, n. 1, p. 21–26, 2006.
MUECKLER, M. Facilitative glucose transporters. European Journal of Biochemistry, v. 219, n. 3, p. 713–725, 1994a.
MUECKLER, M. Facilitative glucose transporters. European Journal of Biochemistry, v. 219, n. 3, p. 713–725, 1994b.
NAVEEN, Y. P. et al. Phytochemical Composition and In vitro Anti-Hyperglycemic Potency of Eucalyptus tereticornis Bark. Indian J Nutri., v. 1, n. 1, p. 1–6, 2014.
NEWELL, A. M. B. et al. Comparative in vitro bioactivities of tea extracts from six species of Ardisia and their effect on growth inhibition of HepG2 cells. Journal of Ethnopharmacology, v. 130, n. 3, p. 536–544, 9 ago. 2010.
PAVAN KUMAR, P. et al. Synthesis and biological evaluation of bergenin-1,2,3-triazole hybrids as novel class of anti-mitotic agents. Bioorganic Chemistry, v. 91, p. 103–161, 2019a.
PAVAN KUMAR, P. et al. Synthesis and biological evaluation of bergenin-1,2,3-triazole hybrids as novel class of anti-mitotic agents. Bioorganic Chemistry, v. 91, p. 103–161, out. 2019b.
QIAO, S. et al. Bergenin impedes the generation of extracellular matrix in glomerular mesangial cells and ameliorates diabetic nephropathy in mice by inhibiting oxidative stress via the mTOR/β-TrcP/Nrf2 pathway. Free Radical Biology & Medicine, v. 145, p. 118–135, dez. 2019.
SAKLAYEN, M. G. The Global Epidemic of the Metabolic Syndrome. Current Hypertension Reports, v. 20, n. 2, p. 12, 26 fev. 2018.
SAN, H. T. et al. Bergenin from Cissus javana DC. (Vitaceae) root extract enhances glucose uptake by rat L6 myotubes. Tropical Journal of Pharmaceutical Research, v. 19, n. 5, p. 1081–1086, 2020.
SHI, X. et al. Anticancer activity of bergenin against cervical cancer cells involves apoptosis , cell cycle arrest , inhibition of cell migration and the STAT3 signalling pathway. Journal Experimental and Therapeutic Medicine, v. 18, n. 4, p. 3525–3529, 2019.
SHIKOV, A. N. et al. Effect of Bergenia crassifolia L. extracts on weight gain and feeding behavior of rats with high-caloric diet-induced obesity. Phytomedicine, v. 19, n. 14, p. 1250–1255, 2012.
SILVA, L. R.; TEIXEIRA, R. Phenolic profile and biological potential of Endopleura uchi extracts. Asian Pacific Journal of Tropical Medicine, v. 8, n. 11, p. 889–897, 2015a.
SILVA, L. R.; TEIXEIRA, R. Phenolic profile and biological potential of Endopleura uchi extracts. Asian Pacific Journal of Tropical Medicine, v. 8, n. 11, p. 889–897, 2015b.
SLANC, P. et al. Screening of Selected Food and Medicinal Plant Extracts for Pancreatic Lipase Inhibition. Phytotherapy Research, v. 22, n. 4, p. 544–549, 2008.
SRIKANTHAN, K. et al. Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. International Journal of Medical Sciences, v. 13, n. 1, p. 25–38, 2016.
SRIVASTAVA, G.; APOVIAN, C. M. Current pharmacotherapy for obesity. Nature Reviews. Endocrinology, v. 14, n. 1, p. 12–24, 2018.
SUBRAMANIAN, R.; ASMAWI, M. Z.; SADIKUN, A. In vitro α-glucosidase and α-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide. Acta Biochimica Polonica, v. 55, n. 2, p. 391–398, 2008a.
SUBRAMANIAN, R.; ASMAWI, M. Z.; SADIKUN, A. In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide. Acta Biochimica Polonica, v. 55, n. 2, p. 391–398, 2008b.
TADERA, K. et al. Inhibition of α-glucosidase and α-amylase by flavonoids. Journal of Nutritional Science and Vitaminology, v. 52, n. 2, p. 149–153, 2006.
VIJAYA KUMAR, T. et al. Synthesis and antiglycation potentials of bergenin derivatives. Bioorganic and Medicinal Chemistry Letters, v. 21, n. 16, p. 4928–4931, 2011.
WANG, K. et al. Bergenin, Acting as an Agonist of PPARγ, Ameliorates Experimental Colitis in Mice through Improving Expression of SIRT1, and Therefore Inhibiting NF-κB-Mediated Macrophage Activation. Frontiers in Pharmacology, v. 8, p. 981, 2017.
WILLIAMS, L. K. et al. The amylase inhibitor montbretin A reveals a new glycosidase inhibition motif. Nature Chemical Biology, v. 11, n. 9, p. 691–696, 2015.
WOLFE, K. L.; LIU, R. H. Cellular antioxidant activity (CAA) assay for assessing antioxidants, foods, and dietary supplements. Journal of Agricultural and Food Chemistry, v. 55, n. 22, p. 8896–8907, 2007.
XIANG, S. et al. Bergenin exerts hepatoprotective effects by inhibiting the release of inflammatory factors, apoptosis and autophagy via the PPAR-γ pathway. Drug Design, Development and Therapy, v. 14, p. 129–143, 2020.
XU, H. et al. Etiology of Metabolic Syndrome and Dietary Intervention. International Journal of Molecular Sciences, v. 20, n. 1, p. 128, 31 dez. 2018.
ZHANG, J. et al. Pancreatic lipase inhibitory activity of taraxacum officinale in vitro and in vivo. Nutrition Research and Practice, v. 2, n. 4, p. 200, 2008.
